Sonova (OTCMKTS:SONVY) Stock Rating Upgraded by Zacks Research

Sonova (OTCMKTS:SONVY) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

SONVY has been the topic of a number of other research reports. BNP Paribas Exane began coverage on Sonova in a research note on Monday, October 20th. They issued an “underperform” rating on the stock. Royal Bank Of Canada upgraded shares of Sonova to a “moderate buy” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Sonova Trading Down 0.2%

Shares of OTCMKTS:SONVY opened at $53.40 on Monday. The company’s fifty day moving average price is $52.89 and its 200-day moving average price is $54.48. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.24 and a quick ratio of 0.91. Sonova has a one year low of $47.55 and a one year high of $68.76.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.